Medical journal advertising campaigns should be pretested and evaluated in order to address user concerns. Any degree of confusion or perceived clutter must be addressed.
Not all medical advertising is effective. If a promotional approach doesn’t work, this research shows that it can be the results of a problem ad campaign or inconsistency in messaging and not the fault of the medium.
It is mandatory to analyze campaign effectiveness using both attitudinal and behavioral techniques. A behavioral (Rx) analysis is designed to determine if the program raised sales, while the attitudinal analysis explains the results. This combined methodology allows necessary adjustments to be made, if needed, to improve the probability of success.
The PosTest research in this study supports the concept that for medical journal advertising to be effective, it is important for a series of events to take place (campaign awareness, message penetration and change in 1st choice therapy) in advance of increased prescriptions.
There is evidence that medical advertising can raise the level of perceived detailing when it connects with the sales aid.
Medical journal advertising can work and this research confirmed that at an appropriate level the medical advertising created awareness, communicated its message, raised 1st choice therapy and raised sales in both the six-month and twelve-month measurement periods.
Anatomy of a Success Advertising PreTest Results Product A
The CTS PreTest conducted prior launch indicated that Product “A’s” journal advertisement would be well received pending minor changes relative to message placement and the location of fair balance.
The recommended changes were made.
There Is A Direct Relationship Between The Ad Budget And Campaign Awareness. Higher Levels Of Advertising Help To Communicate The Ad’s Message And Increased Use As First Choice Therapy Product “A” (Awareness Scores) Ad Recognition Product Recall Correct Message Association* 1 St Choice Therapy *Subsequently it was learned that the ad message was inconsistent with the message detailed by the reps. PosTest Results 44 26 29 32% 44 23 16 11% 38 58 T 3 ($3,500,000) 32 45 T 2 ($1,750,000) 30 44 T 1 ($ 875,000) 31% 21% Control
It Appears That Higher Levels of Advertising Reinforce The Perception Of Being Detailed Physician Awareness of Being Detailed vs. Company Records * Percent indicating they are routinely detailed (monthly or quarterly) ** Percent of panel MD’s (Control/Test) detailed on this product. 42% 41% 40% 40% Company Records ** 52% 46% 38% 43% Physician Response * T 3 T 2 T 1 Control
Higher Levels of Advertising Produced a Significant Increase in NRx’s Test Group III *Statistically significant at 95% level of confidence Significant Difference Test vs. Control 10.47%* 1 st 12 months 11.07%* 2 nd 6 months 9.79%* 1 st 6 months Prod “A”
Anatomy of a Failure Advertising PreTest Results Product “B”
While physicians responded favorably to the main message, more than half (57%) were unsure or negative about the visual with such comments as:
“ Too busy”
“ Too much”
“ Too crowded”
“ Way too busy for an ad, the small print at the bottom of the page looks terrible”
It was recommended to expand the ad size from 2 pages to 4 to correct overcrowding; However, this was not done.
Awareness Of The Ad, The Product it Promoted And Correct Product Association With The Main Messages Did Not Grow With Additional Ad Spending Product “B” (Awareness Scores) Ad Recognition Product Recall *Could have been seen in specialty journal or as part of a sales aid. Six Months PosTest Results Correct Message Association 51% 59% 51% 52% 34% 45% T 3 ($3,000,000) 29% 48% T 2 ($1,500,000) 30% 40% T 1 ($ 750,000) 33*% 46*% Control ($0)
There Is No Relationship Between Tested Ad Budgets And Consideration Of Product “B” For Its Major Indication Product “B” % 1 st Choice Therapy By Indication 40% 44% 48% 47% Condition #1 T 3 T 2 T 1 Control
THERE IS NO INDICATION THAT HIGHER AD EXPENDITURES PRODUCED HIGHER GROWTH Product “B” Management Summary PCP Nx Results No Significant Difference Test vs. Control 43.8% T 3 46.5% T 2 44.3% T 1 45.2% Control % Change New Rx’s/Mo Mar-Aug ’03/’04 Area
Behavioral Research Conducted By: Dick R. Wittink, Ph.D. Yale On Medical Journal ROI
Medical Journal Advertising Delivers The Highest Return On Investment Among All Four Key Marketing Activities
This Plus Its Small Share Of Medical Promotion Expenditures, Suggests That Medical Journal Advertising Is Under Utilized
Spending the Right Amount In Medical Journals Can Enhance The ROI For All Types Of Brands, Small Or Large, New Or Established.
Overall Return On Investment* *Based on an analysis of 392 branded drugs and 21,436 monthly observations from 1995 to 2000. $ 1.30 Direct-to-Customer $11.60 Detailing $11.70 Physicians, Meetings & Events $12.20 Medical Journal Advertising
Conclusion Given the proven strength of Medical Journal Advertising, companies should consider utilizing this medium to a greater extent in the mix to make marketing: